<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864435</url>
  </required_header>
  <id_info>
    <org_study_id>3159</org_study_id>
    <nct_id>NCT00864435</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions</brief_title>
  <official_title>A Two-Way Crossover, Open-Label, Single Dose, Fasting, Bioequivalence Study of Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets in Normal, Healthy, Non-Smoking Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the rate and extent of absorption of carvedilol from a test formulation of
      Carvedilol 12.5 mg Tablets versus the reference Coreg® 12.5 mg Tablets under fasting
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Two-way crossover, randomized, open-label,
      single-dose, fasting, bioequivalence study

      Official Title: A Two-Way Crossover, Open-Label, Single Dose, Fasting, Bioequivalence Study
      of Carvedilol 12.5 mg Tablets Versus Coreg® 12.5 mg Tablets in Normal, Healthy, Non-Smoking
      Male and Female Subjects

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol 12.5 mg Tablets, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coreg® 12.5 mg Tablets , single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol 12.5 mg Tablets, single dose</intervention_name>
    <description>A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coreg® 12.5 mg Tablets , single dose</intervention_name>
    <description>B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Carvedilol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Non-smoking male or female with a minimum age of 18 years.

          2. Body Mass Index (BMI = weight/heigh2) greater than or equal to 18.5 kg/m2 and less
             than or equal to 29.9 kg/m2

          3. Normal findings in the physical examination, 12-lead ECG and vital signs (blood
             pressure between 106-140/66-90 mmHg, heart rate between 60-99 beats/minute,
             temperature between 35.8°C and 37.5°C)

          4. Negative for drugs of abuse and nicotine.

          5. Negative for hepatitis B-surface antigen, hepatitis C and HIV.

          6. Female subjects: negative for pregnancy (as evaluated by serum ß-CG test).

          7. No clinical laboratory values outside of the acceptable range as defined by BCR,
             unless the Principal Investigator decides that they are not clinically significant.

          8. Female subjects who were surgically sterile for at least 6 months or post-menopausal
             for at least 1 year, or avoided pregnancy for at least 10 days before the study,
             during the study and up until 1 month after the end of the study.

          9. Availability of the subject for the entire study period and willingness of the subject
             to adhere to protocol requirements, as evidenced by a signed ICF

        Exclusion Criteria:

          1. Known history of hypersensitivity to carvedilol (e.g. Coreg®) and/or related
             beta¬blockers such as propranolol (Inderal®, nadolol (Corgard®), labetalol (Trandate®,
             metoprolol (Lopressor®, Betaloc®, atenolol (Tenormin®, sotalol, timolol, pindolol, or
             acebutolol.

          2. Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine,
             musculoskeletal, neurological, hematological, liver or kidney disease, unless deemed
             not clinically significant by the Principal Investigator or Sub-investigator.

          3. Presence of any significant physical or organ abnormality.

          4. Any history or evidence of psychiatric or psychological disease (including depression)
             unless deemed not clinically significant by the Principal Investigator or
             Sub-investigator.

          5. Known history of frequent headaches or migraines.

          6. Known history of chronic bronchitis or any bronchospastic condition.

          7. Any clinically significant illness during the 4 weeks before this study.

          8. Known history or presence of food allergies, or any condition known to interfere with
             the absorption, distribution, metabolism or excretion of drugs.

          9. Any history of severe allergic reaction (including drugs, food, insect bites,
             environmental allergens).

         10. Significant or recent history of asthma (after 12 years of age).

         11. Any subject with a history of drug abuse.

         12. Any subject with a recent (less than 1 year) history of alcohol abuse.

         13. Use of any prescription medication within 14 days preceding this study.

         14. Use of any over-the-counter (OTC) cough and cold medication containing
             dextromethorphan within 14 days preceding this study.

         15. Use of OTC medication within 7 days preceding this study (except for
             spermicidal/barrier contraceptive products).

         16. Female subjects: use of contraceptives (oral, emergency [plan B®, transdermal,
             implant, Mirena® IUD, NuvaRing®) within 30 days before drug administration or a depot
             injection of progestogen drug (e.g. Depo-Provera® within 1 year before drug
             administration.

         17. Female subjects: evidence of pregnancy or lactation.

         18. Any subject who had blood drawn within 56 days preceding this study, during the
             conduct of any clinical study at a facility other than BCR, or within the lockout
             period specified by a previous study conducted at BCR.

         19. Participated in a clinical trial with an investigational drug within 30 days preceding
             this study.

         20. Any subject who had donated blood within 56 days preceding this study.

         21. Any subject who had participated as a plasma donor in a plasmapheresis program within
             7 days preceding this study.

         22. Intolerance to venipuncture.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Y. Tam,, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biovail Contract Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biovail Contract Research (A Division of Biovail Corporation)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M1L 4S4 / M1L 4R6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://chem.sis.nlm.nih.gov/chemidplus/ProxyServlet?objectHandle=DBMaint&amp;actionHandle=default&amp;nextPage=jsp/chemidlite/ResultScreen.jsp&amp;TXTSUPERLISTID=072956093</url>
    <description>CARVEDILOL</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Carvedilol</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

